Johnson & Johnson’s Janssen Pharmaceuticals division is providing refunds to 340B covered entities for overcharges on 14 NDCs during Q1 2020.
The U.S. Health Resources and Services Administration (HRSA) posted J&J’s refund notice yesterday. The company said the 340B price revisions “were due to standard restatements of Medicaid pricing data made to” the Centers for Medicare & Medicaid Services.
“Janssen will be communicating with and issuing refund adjustments through the wholesalers that submitted the original sale on behalf of the 340B covered entities,” the notice says. It includes contact information “if you feel you have not received an appropriate adjustment.”
Janssen becomes the second drug manufacturer to announce refunds in the 2023 year. As we reported on Wednesday, Alcon said it is providing refunds for charges above 340B ceiling prices on 22 NDCs for varying sales periods from Q3 2019 through Q3 2022. HRSA posted Alcon’s public notice about the refunds to 340B covered entities on Jan 3.
HRSA last year posted 34 notices by drug manufacturers to covered entities about refunds for charges above 340B ceiling prices, more than double the 16 posted in 2021 and 15 in 2020. There were seven in 2019. The notices have become more common since January 2019 when manufacturers first became subject to civil monetary penalties for knowing and intentional 340B overcharges.
